Data on sprytne.com is aggregated from official U.S. Government sources including the SEC EDGAR database, USAspending.gov, USPTO, and U.S. Census Bureau. In accordance with 17 U.S.C. § 105, works of the U.S. Government are not subject to copyright protection and reside in the Public Domain. sprytne.com provides value-added visualization and algorithmic analysis of these public records.
Not financial advice. sprytne.com is an automated market intelligence platform. We are not a registered investment advisor, broker, or dealer. Financial metrics, risk scores, and federal award data are for informational purposes only. Past performance (including government contract history) is not indicative of future market results. Verify all data via official SEC.gov filings.
This platform adheres to CCPA/GDPR standards regarding professional and public business data. Information displayed pertains to commercial entities and public officers in their professional capacity. For data verification or removal requests regarding non-public information, please visit our Contact page. Operated under Brand House Data Systems framework.
© 2026 sprytne.com — Institutional Data Intelligence — Federal Transparency Initiative
Financial benchmark analysis for 595 SEC-registered companies.
Sector Intelligence · Sprytne.com
The Pharmaceutical Preparations sector (SIC 2834) is led by JOHNSON & JOHNSON with $94.19B in annual revenue. Meanwhile, Viridian Therapeutics, Inc.\DE leads in growth at +23359.9% YoY.
Based on the latest SEC EDGAR 10-K annual filings · Verified public data
Filter by State
| Rank | Company | Revenue | Details |
|---|---|---|---|
| #1 | JOHNSON & JOHNSONJNJ | $94.19B | YoY: +6.0% |
| #2 | ELI LILLY & CoLLY | $65.18B | YoY: +44.7% |
| #3 | Merck & Co., Inc.MRK | $65.01B | YoY: +1.3% |
| #4 | AbbVie Inc.ABBV | $61.16B | YoY: +8.6% |
| #5 | PFIZER INCPFE | $50.91B | YoY: -44.5% |
| #6 | BRISTOL MYERS SQUIBB COBMY | $48.19B | YoY: -0.2% |
| #7 | ABBOTT LABORATORIESABT | $44.33B | YoY: +5.7% |
| #8 | TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA | $17.26B | YoY: +4.3% |
| #9 | REGENERON PHARMACEUTICALS, INC.REGN | $14.34B | YoY: +1.0% |
| #10 | Viatris IncVTRS | $14.25B | YoY: -3.0% |
| #11 | VERTEX PHARMACEUTICALS INC / MAVRTX | $12.00B | YoY: +8.9% |
| #12 | Bausch Health Companies Inc.BHC | $10.27B | YoY: +6.7% |
| #13 | Zoetis Inc.ZTS | $9.47B | YoY: +2.3% |
| #14 | Organon & Co.OGN | $6.22B | YoY: -2.9% |
| #15 | BeOne Medicines Ltd.ONC | $5.34B | YoY: +40.2% |
| #16 | Elanco Animal Health IncELAN | $4.71B | YoY: +6.2% |
| #17 | Jazz Pharmaceuticals plcJAZZ | $4.27B | YoY: +4.9% |
| #18 | PERRIGO Co plcPRGO | $4.25B | YoY: -2.8% |
| #19 | ALNYLAM PHARMACEUTICALS, INC.ALNY | $3.71B | YoY: +65.2% |
| #20 | BIOMARIN PHARMACEUTICAL INCBMRN | $3.22B | YoY: +12.9% |
| #21 | UNITED THERAPEUTICS CorpUTHR | $3.18B | YoY: +10.6% |
| #22 | Amneal Pharmaceuticals, Inc.AMRX | $3.02B | YoY: +8.0% |
| #23 | Royalty Pharma plcRPRX | $2.38B | YoY: +5.1% |
| #24 | Sarepta Therapeutics, Inc.SRPT | $1.86B | YoY: +4.3% |
| #25 | PTC THERAPEUTICS, INC.PTCT | $1.73B | YoY: +114.5% |
| Rank | Company | YoY Growth | Details |
|---|---|---|---|
| #1 | Viridian Therapeutics, Inc.\DEVRDN | +23359.9% | Revenue: $70.8M |
| #2 | ARROWHEAD PHARMACEUTICALS, INC.ARWR | +23258.2% | Revenue: $829.4M |
| #3 | Keros Therapeutics, Inc.KROS | +6775.0% | Revenue: $244.1M |
| #4 | Septerna, Inc.SEPN | +4174.5% | Revenue: $46.0M |
| #5 | Spero Therapeutics, Inc.SPRO | +3292.5% | Revenue: $12.6M |
| #6 | IDEAYA Biosciences, Inc.IDYA | +3024.4% | Revenue: $218.7M |
| #7 | TherapeuticsMD, Inc.TXMD | +2619.1% | Revenue: $70.0M |
| #8 | Liquidia CorpLQDA | +1031.2% | Revenue: $158.3M |
| #9 | Nuvation Bio Inc.NUVB | +699.0% | Revenue: $62.9M |
| #10 | Syndax Pharmaceuticals IncSNDX | +627.8% | Revenue: $172.4M |
| #11 | Atea Pharmaceuticals, Inc.AVIR | +622.5% | Revenue: $351.4M |
| #12 | CorMedix Inc.CRMD | +617.0% | Revenue: $311.7M |
| #13 | Xilio Therapeutics, Inc.XLO | +589.9% | Revenue: $43.8M |
| #14 | SCYNEXIS INCSCYX | +449.9% | Revenue: $20.6M |
| #15 | MADRIGAL PHARMACEUTICALS, INC.MDGL | +432.1% | Revenue: $958.4M |
| #16 | Stoke Therapeutics, Inc.STOK | +404.5% | Revenue: $184.4M |
| #17 | CYTOKINETICS INCCYTK | +376.6% | Revenue: $88.0M |
| #18 | ZEVRA THERAPEUTICS, INC.ZVRA | +350.9% | Revenue: $106.5M |
| #19 | Verastem, Inc.VSTM | +285.2% | Revenue: $10.0M |
| #20 | NextCure, Inc.NXTC | +252.6% | Revenue: $22.4M |
| #21 | Phathom Pharmaceuticals, Inc.PHAT | +216.9% | Revenue: $175.1M |
| #22 | Cue Biopharma, Inc.CUE | +195.7% | Revenue: $27.5M |
| #23 | Earth Science Tech, Inc.ETST | +177.1% | Revenue: $33.1M |
| #24 | Vireo Growth Inc.VREOF | +170.4% | Revenue: $268.8M |
| #25 | AbCellera Biologics Inc.ABCL | +160.6% | Revenue: $75.1M |
| Rank | Company | Net Income | Details |
|---|---|---|---|
| #1 | JOHNSON & JOHNSONJNJ | $26.80B | Margin: 28.5% |
| #2 | ELI LILLY & CoLLY | $20.64B | Margin: 31.7% |
| #3 | Merck & Co., Inc.MRK | $18.25B | Margin: 28.1% |
| #4 | PFIZER INCPFE | $7.77B | Margin: 15.3% |
| #5 | BRISTOL MYERS SQUIBB COBMY | $7.05B | Margin: 14.6% |
| #6 | ABBOTT LABORATORIESABT | $6.52B | Margin: 14.7% |
| #7 | REGENERON PHARMACEUTICALS, INC.REGN | $4.50B | Margin: 31.4% |
| #8 | AbbVie Inc.ABBV | $4.23B | Margin: 6.9% |
| #9 | VERTEX PHARMACEUTICALS INC / MAVRTX | $3.95B | Margin: 32.9% |
| #10 | Zoetis Inc.ZTS | $2.67B | Margin: 28.2% |
| #11 | TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA | $1.41B | Margin: 8.2% |
| #12 | UNITED THERAPEUTICS CorpUTHR | $1.33B | Margin: 41.9% |
| #13 | Royalty Pharma plcRPRX | $770.9M | Margin: 32.4% |
| #14 | PTC THERAPEUTICS, INC.PTCT | $682.6M | Margin: 39.4% |
| #15 | TG THERAPEUTICS, INC.TGTX | $447.2M | Margin: 72.6% |
| #16 | ACADIA PHARMACEUTICALS INCACAD | $391.0M | Margin: 36.5% |
| #17 | RIGEL PHARMACEUTICALS INCRIGL | $367.0M | Margin: 124.7% |
| #18 | BIOMARIN PHARMACEUTICAL INCBMRN | $348.9M | Margin: 10.8% |
| #19 | BeOne Medicines Ltd.ONC | $286.9M | Margin: 5.4% |
| #20 | Alkermes plc.ALKS | $241.7M | Margin: 16.4% |
| #21 | Prestige Consumer Healthcare Inc.PBH | $214.6M | Margin: 18.9% |
| #22 | CATALYST PHARMACEUTICALS, INC.CPRX | $214.3M | Margin: 36.4% |
| #23 | Indivior Pharmaceuticals, Inc.INDV | $210.0M | Margin: 16.9% |
| #24 | Organon & Co.OGN | $187.0M | Margin: 3.0% |
| #25 | KYNTRA BIO, INC.KYNB | $183.5M | Margin: 2848.6% |